Status:

UNKNOWN

Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue

Lead Sponsor:

Alta Bates Summit Medical Center

Conditions:

Fatigue

Eligibility:

All Genders

18-64 years

Phase:

PHASE3

Brief Summary

This is a randomized, placebo controlled study in cancer patients reporting fatigue persisting for at least two months following completion of chemotherapy. Subjects will receive 6 weeks of either acu...

Eligibility Criteria

Inclusion

  • Patients age 18-64 diagnosed with a malignancy (solid tumor or hematologic malignancy).
  • Patients must have received chemotherapy.
  • Patients must complain of fatigue following chemotherapy buy not prior to chemotherapy.
  • At least 60 days must have elapsed between the last chemotherapy infusion and completion of the first baseline questionnaire.
  • Mean baseline fatigue as measured by the Brief Fatigue Inventory must be four or above.

Exclusion

  • Anemia, defined as Hb\<9 or active treatment for anemia. Iron supplementation is allowed as long as the dose has been stable for at least six weeks.
  • Platelets less than 50,000/microliter or an Absolute Neutrophil Count less than 1,000/microliter.
  • Baseline depression score on the Hospital Anxiety and Depression Scale of 11 or above, indicating clinical depression.
  • Thyroid disorder, defined as either thyroid stimulating hormone or free T4 out of normal range, is excluded as it is a possible cause of fatigue unrelated to cancer therapy.
  • Surgery under general anesthesia; immunotherapy; radiotherapy; or initiation of hormonal therapy within the three weeks prior to enrollment.
  • Acupuncture in the previous six weeks.
  • Change in use of any of the following drugs in the prior three weeks: opiates, antidepressants (other than selective serotonin reuptake inhibitors \[SSRIs\])/anxiolytics; OR change in use of SSRIs in the prior six weeks. "Change in use" is defined as initiation or cessation of treatment, or change in prescribed dose or regimen: changes in actual amounts of PRN medication taken are allowed.

Key Trial Info

Start Date :

April 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2011

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT00658034

Start Date

April 1 2008

End Date

December 1 2011

Last Update

October 26 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Alta Bates Summit Comprehensive Cancer Center

Berkeley, California, United States, 94704